Accordingly, regulating PFKFB3, particularly through small molecule inhibitors, offers a promising strategy for improving glucose metabolism disorders in AP (Lu et al. 2021; Selinger et al. 2022). The gene discussed is PFKFB3; the disease is glucose metabolism disease.